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Abstract Indirect immunofluorescence (IIF) using human
epithelial cell (HEp-2) substrate is a widely used and the
recommended method for screening of antinuclear anti-
bodies (ANA). Dense fine speckled (DFS70) pattern on
HEp-2 has been widely reported in various healthy and
disease groups. Interpretation of DFS70 pattern can be
challenging on a conventional HEp-2 substrate due to its
similarity to some of the disease associated patterns. The
high prevalence of DFS70 autoantibodies in normal pop-
ulation, lack of association with a particular disease group
and a general negative association with systemic and ANA
associated autoimmune rheumatic diseases (SARD/AARD)
necessitates the confirmation of DFS70 pattern. Results
using available commercial assays for confirmation of
DFS70 autoantibodies do not always agree with IIF
screening results further complicating the lab work flow
and ANA algorithms. In this review, we discuss the
prevalence of DFS70 antibodies and factors affecting the
performance of IIF and DFS70 specific confirmatory
assays. Factors that contribute to disagreement between
DFS70 suspicion by IIF and confirmatory assays will also
be discussed. In addition, we also describe a novel IIF
HEp-2 substrate, and its positive impact on DFS70
reporting and ANA screening-confirmation algorithm.
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DFS70 Dense fine speckled 70
EIA/ELISA Enzyme-linked immunosorbent assay
ICAP International consensus on ANA pattern
IIF Indirect immunofluorescence
LEDGF Lens epithelium derived growth factor
AARD ANA associated rheumatic diseases
SARD Systemic autoimmune rheumatic diseases
Introduction
ANAs remain a hallmark of systemic autoimmune dis-
eases. Patterns of ANA observed on HEp-2 cells by IIF
provide the clinicians with insight into specificity of
autoantibodies present, indications of disease likelihood
and further implicate or rule out a clinical suspicion [1]. IIF
by HEp-2 is a widely prevalent screening method among
the techniques used for the determination of ANA. Despite
advances in EIA/ELISA/multiplex methodologies for
screening of ANAs, IIF-HEp-2 remains one of the most
prevalent methods due to its diagnostic usefulness and cost
effectiveness. HEp-2 cells are able to present a variety of
autoantigens that result in a multitude of distinct patterns.
Though this method has been widely used for more than
50 years, standardization of the quality of HEp-2 substrates
(clones, growth phase, fixation method), strength and
specificity of FITC-conjugates (fluorescein isothiocyanate),
F/P ratio (fluorescein/protein molar ratio), anti-human IgG
specificity (Heavy chain/light chain/Fc region), washing
technique, buffers, counterstain, microscope setup (exci-
tation light source, use of neutral density filters, narrow/
broad band emission filters, quality and specifications of
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objectives) is lacking. In addition to this, technical exper-
tise and human subjectivity of the readers can impact
accurate interpretation of IIF [2]. In an effort to standardize
the IIF, International consensus on ANA patterns (ICAP)
workshops recommend a consensus nomenclature for the
HEp-2 patterns and provide training and description of the
nuclear/cytoplasmic/mitosis stage specific patterns on
HEp-2 and their antigen/disease associations [3]. The ICAP
committee described 28 distinct patterns on HEp-2 and
assigned each pattern an AC (Anti-cell) number of 1–28
[3]. DFS70 AC-02 pattern has received the most scrutiny in
the field in recent years due to its high rates of prevalence
in healthy and ANA positive populations and negative
association with SARD/AARD [4, 5].
DFS70 pattern: background
The DFS70 pattern resulting from autoantibodies binding
to the ubiquitously expressed protein called lens epithelium
derived growth factor (LEDGF) or p75 or psip1 gene
product is frequently observed during routine ANA
screening by IIF-HEp-2. DFS70 pattern and autoantibodies
were originally described by Ochs et al. [8] and were later
confirmed in higher frequencies in patients with atopic
dermatitis and asthma [6, 7] (Fig. 1). DFS70 is a unique
pattern characterized by dense and heterogeneous fine
speckled staining of the nucleoplasm in interphase, and
speckled staining tightly associated with chromatin during
mitosis [7–9]. Independent efforts by various groups have
unraveled the identity of the gene encoding this antigen and
resulted in characterization of the role of LEDGF/psip1/
p75 [7, 10–13]. DFS70/LEDGF/p75 is a ubiquitously
expressed growth/transcription factor that localizes to the
cell nucleus. The N-terminus has a high affinity for chro-
matin binding due to which the autoantigen remains tightly
associated with chromatin during entire cell cycle
[7, 14–16]. Epitope mapping analysis of the DFS70
autoantigen revealed a conformational autoepitope on the
C-terminus of the antigen which was responsible for
majority of the DFS70 autoantibody binding [17]. DFS70
pattern resulting from LEDGF/p75 gained major attention
of the diagnostic field when Watanabe and colleagues
reported that 11.6% (64) of the 597 healthy hospital
workers in Japan were positive for DFS70 pattern [18].
Role of DFS70/LEDGF/p75 antigen as a transcription
factor, cellular co-factor of HIV-1 integration, m-RNA
splicing, cell-stress survival factor, its potential interaction
with STAT3 in IL-6/STAT3 inflammatory pathway has
been reviewed by Casiano and co-workers [19–25]. The
mechanism underlying the appearance and the clinical
impact of DFS70 antibodies is not yet clear but these have
been reported by various groups across the world in both
healthy and disease populations. It is still unknown if the
DFS70 autoantibodies are natural and protective or
pathogenic. Inaccurate interpretation and reporting of AC-
02 as one of the disease associated ANA patterns (homo-
geneous/AC-01, fine speckled/AC-04, speckled/AC-05 or a
combination of AC-01/AC-04/AC-05) can lead to unnec-
essary testing and negatively impact patient care. Due to
their high prevalence in ANA screening population and
lower association with SARD/AARD, ICAP committee
recommends all clinical labs to report the DFS70 pattern
[3].
DFS70 pattern: impact on ANA screening
and reporting
With the increased demand for ANA testing, many labs
have switched to newer solid phase and multiplex
methodologies for screening of ANAs [2]. Although these
methods are automation friendly and reduce subjectivity in
the interpretation of results, they are based on a limited
number of purified recombinant/native autoantigens and do
not equate in performance to HEp-2 IIF [2]. The American
College of Rheumatology(ACR) position statement
describes IIF-HEp-2 as the gold standard method for ANA
testing [26, 27]. The HEp-2 cell represents at least 100–150
autoantigens in native configuration which provide the
unique pattern and titer. This information is of useful value
to clinical labs in determining the positive/negative ANA
status and selection of appropriate solid phase confirmatory
assays [26, 27]. In addition to the ACR, the European
•Discovery of autoantibodies recognizing a  nuclear dense fine speckled 
pattern in patients with interstitial cystitis
1994
•Detecon of cytotoxic an-LEDGF autoanbodies in atopic dermas
1999
•Characterizaon of DFS70 paern (LEDGF autoangen) using anbodies 
from paents with atopic dermas & DFS70 autoanbodies are present at 
low frequencies in SARD paents
2000
•Characterizaon of DFS70/LEDGF/p75 autoangen
1999-2004
•DFS70 autoanbodies are present in apparently healthy individuals
2004
•Availability of various commercial DFS70 speciﬁc conﬁrmatory assays
•DFS70 autoanbodies are frequent in general and ANA posive populaon
•DFS70 autoanbodies are rarely diagnosed in SARD and when present, they 
accompany a disease speciﬁc paern/anbody along with DFS70 in majority 
of the cases
•DFS70 proposed as an exclusion marker for SARD
2005-present
DFS70/LEDGF/p75 autoantibodies - Background and significance
Fig. 1 Background, significance and various milestones associated
with the discovery and characterization of DFS70 autoantibodies is
described
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autoimmunity standardization initiative group also recog-
nizes the IIF-HEp-2 as reference method despite identify-
ing some of the advantages offered by solid
phase/multiplex assays [2]. IIF-HEp-2 is the first step of the
routine screening of ANAs and if the IIF result is negative,
the samples are not tested further unless there is a strong
clinical suspicion (Figs. 2, 3). IIF positive results are ana-
lyzed for pattern and titer. Classic disease associated ANA
patterns, AC-01 to AC-28 with the exception of AC-02 are
further confirmed on appropriate solid phase assays
(Figs. 2, 3). Due to the efforts of ICAP and work of experts
in the field, clinical laboratories around the world are
gaining an understanding of DFS70/AC-02 pattern. DFS70
specific commercial assays are now available for routine
use in the form of ELISA/EIA, CLIA/CIA, line blot or dot
blot and modified IIF (selective adsorption IIF) procedures
(Fig. 2). For research and confirmation of suspected sam-
ples, some labs are also using IP (immunoprecipitation)
and Western blot assays with cell lysates (HeLa, HEpG2,
HEp-2, Jurkat or PC3 cell lines) known to express ample
levels of LEDGF/DFS70 protein [25, 28, 29].
Prevalence of DFS70 autoantibodies
ANA-IIF-HEp-2 is being increasingly requested not only
on clinical suspicion of AARD but also for differential
diagnosis from AARD. In many clinical laboratories,
ANA-IIF referrals come from rheumatologists, hepatolo-
gists, neurologists, dermatologists, allergy/immunologists
and increasingly from general practitioners to rule out
SARD. Based on this trend, the complexity and
heterogeneity of ANA screening populations change sig-
nificantly from one clinical lab to the other. Systematic
review for DFS70 autoantibody positivity has been per-
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Fig. 2 Schematic summarizes
the current generation of
diagnostic assays used for
confirmation of DFS70 pattern
and how they are used in the
context of ANA screening
algorithm
Screening by convenonal HEp2-IIF
Posive




Conﬁrm by DFS70 
speciﬁc assays (Figure 2)
Negave Posive







Current diagnostic algorithm using conventional HEp-2 IIF method
Negave: No follow up
Fig. 3 Schematic describes the current diagnostic algorithm for
screening ANAs in many labs. IIF using HEp-2 substrates is the first
step. Cases that are negative do not need follow up. Positive cases are
analyzed for pattern and titer. If disease associated ANA patterns are
suspected, respective confirmatory assay/assays are performed. If
DFS70/homogenous ? speckled mixed pattern is suspected, DFS70
specific confirmatory assays are performed. Both positive and
negative DFS70 results on confirmatory assays may warrant addi-
tional assays (for autoantibodies towards ENAs, DNA, histone,
nucleosome among the others) as presence of disease associated
ANAs cannot be ruled out
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clinical studies have used IIF-HEp2 for establishing a
suspicion of DFS70 pattern and the rates of positivity for
DFS70 autoantibodies in each group varied widely between
studies [7, 9, 18, 21, 28, 31–44]. DFS70 antibodies have
been reported in high titers from cohorts of healthy indi-
viduals, blood donors, patients being screened for ANA,
patients with various autoimmune disorders and various
non-autoimmune disorders including cancers [4, 6, 30].
These studies have shown that DFS70 autoantibodies lack
distinct clinical association, with most disease groups,
except for certain inflammatory conditions of eyes and skin
[4, 6, 7, 18, 30, 44, 45]. The method of screening, selection,
and composition of study cohorts may also influence the
reported rates of DFS70 autoantibody positivity. A study
by Bizzaro et al. [30] using a highly specific commercial
DFS70-CLIA method as the first screening step, reported
significant variability in DFS70 positivity in clinically
defined cases of anti-phospholipid syndrome (60%),
Hashimoto’s thyroiditis (47.8%), rheumatoid arthritis
(11.1%), Sjogren’s syndrome (4.3%), systemic lupus ery-
thematosus (15.4%), and undifferentiated connective tissue
disease (40%) [30]. One hypothesis for this phenomenon is
that routine ANA screening by IIF method may not reveal
the low levels of DFS70 autoantibodies when disease
associated autoantibodies co-exist. Other theories include
the challenges associated with setting up an appropriate
clinical cut-off value for the confirmatory method.
Based on published studies, a great majority of the
routine ANA screening population is negative for all ANAs
and a large subset of the positive ANA group has DFS70
autoantibodies alone or in combination with other disease
associated ANAs. Due to these factors, this review focuses
on 20 studies from research group around the world that
have reported the frequency of DFS70 suspected cases
(Fig. 4). The selected studies provide results from 78,399
cases from various patient cohort types, including blood
donors (249), healthy individuals (adult: 2793; pediatric:
406), routine ANA screening populations (adult: 59,444;
pediatric: 200), ANA positive healthy individuals (118),
and routine ANA screening cohorts with ANA positive
status (n = 15,189; Fig. 4). The majority of the studies
used IIF-HEp-2 as the screening step, with a few using the
CLIA or ELISA methods. A detailed review of the results
from the selected studies found the rate of DFS70 positivity
to be 0–5% in blood donors, healthy children, and in rou-
tine ANA screening populations. In contrast, cohorts con-
sisting of healthy individuals that have not been
differentiated as pediatric or adults, and ANA positive
cases (healthy or routine ANA screening populations) have
a higher DFS70 pattern positivity ranging from 0 to 37%
(Fig. 4). Group mean for each cohort is indicated by purple
lines in Fig. 3 but due to the heterogeneous nature of
screening populations, geographic diversity, inter-lab
variations in IIF interpretation and accuracy of DFS70
suspicion, the statistics for this data may be of limited
value. However, it is clear from the data that DFS70
autoantibodies are highly prevalent in both healthy and
disease states where SARD is unlikely. Over and under
estimation of DFS70 positivity can have serious impact on
patient care and management and clinical labs are obli-
gated to run a number of reflex tests prior to ruling out a
suspicion of SARD/AARD (Fig. 3). Many reviews by
experts in the field suggested the importance of confirming
DFS70 suspicion using specific methods and evaluate its
overall impact on ANA screening algorithm and associated
costs [1, 4, 6, 30, 34, 39, 46–48]. As per certain studies,
approximately a third of the positive ANA cases were
positive for DFS70 pattern [9, 33]. Due to these com-
plexities associated with DFS70 autoantibodies, the use of
current method of screening significantly increase the
number of confirmatory reflex tests run by labs and the
financial burden for patients and the system.
Gap between DFS70 suspicion by IIF-HEp-2
and confirmatory assays
Variations in IIF HEp-2 substrates, screening dilution
(1:40/1:80/1:160), inter-observer bias (user training,
microscope setup, human subjectivity), FITC-conjugate
strength and mixed ANA patterns with/without DFS70
impact IIF reporting. It is also possible that the antibodies
that produce DFS70 are very heterogeneous and have
increased affinity for full length LEDGF presented in its
natural form bound to chromatin and/or other proteins.
Wide variability in agreements between IIF suspicion and
confirmation by DFS70 specific solid-phase assays have
been reported [28, 30, 39, 49]. Confirmatory assay
parameters that contribute to this disagreement include
differences in antigen selection (full length LEDGF vs.
major antigenic region), recombinant expression system
used for antigen production (E. coli vs. Baculo virus sys-
tem vs. mammalian cells), analytical sensitivity/specificity
of the various assay platforms and the established assay
cut-off. For a pathologist or a clinical laboratory profes-
sional, DFS70 is a distinct pattern that can be differentiated
from other similar disease associated patterns. However,
depending on the titer levels and presence or absence of
other ANA patterns, the interpretation can be challenging
[50]. Expert in the field agree that DFS70 autoantibodies
can occur in presence of other classic ANAs (SARD/
AARD) [37]. Several published studies have suggested the
idea of excluding a suspicion of SARD for DFS70 positive
subjects but they also highlight the importance of con-
firming mono-specific or solitary DFS70 antibody posi-
tivity [4, 48]. Due to these complexities, the clinical labs
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run a panel of reflex assays (ENAs, Anti-DNA, Anti-Nu-
cleosome, Anti-Histone assays among the others) for
DFS70 pattern suspect cases irrespective of the DFS70
solid phase assay results prior to ruling out the absence of
classic ANAs (Fig. 3). Recently proposed selective
absorption IIF method (NovaLite, HEp-2 Select, INOVA
Diagnostics, USA) uses a high concentration of recombi-
nant truncated LEDGF antigen to cross adsorb DFS70
specific autoantibodies in the sample prior to IIF reaction
[51]. Users are expected to implement selective adsorption
procedure on DFS70 suspect samples and evaluate the
relative reduction in the intensity of DFS70 pattern. While
this method attempts to address some of the deficiencies of
other solid phase assays, it is an extra IIF assay step and
there is a likelihood of incomplete adsorption due to high
levels of DFS70 autoantibodies in serum. This possibility
reduces the level of confidence for confirming a mono-
specific DFS70 reaction and may warrant the use of a
second confirmation step for DFS70 and/or multiple con-
firmatory assays for other ANAs.
Fig. 4 Results from 20 different studies pertaining to reported rates
of DFS70 suspicion by IIF/ELISA/CLIA in blood donor, healthy,
ANA screening and ANA positive cohorts are depicted. First authors
of the study, year of publication is followed by samples size and
methods used in brackets. Y- axis represents the percent DFS70
positivity reported in each study. Purple line represents group mean
for each type of cohort
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Screening for classic ANAs, detection
and confirmation of DFS70 antibodies in one step
Here, we introduce a novel HEp-2 IIF substrate (HEp-2
ELITE/DFS70 KO, Immco Diagnostics-Trinity Biotech
USA) that presents a mixture of natural HEp-2 cells and
genetically engineered HEp-2 cells that do not express
DFS70/LEDGF/psip1/p75 antigen (referred to as DFS70
KO cells) in 1:9 ratio on glass slide wells. The new IIF
substrate retains all the capabilities of conventional HEp-2
substrates for screening of ANAs and further is able to
simultaneously detect and confirm with high confidence
both mixed and mono-specific/isolated DFS70 patterns
(Fig. 5). Figure 5a–c illustrates how, conventional HEp-2
cells (interphase and mitosis) present classic homogeneous,
speckled and DFS70 patterns in natural pattern as expected.
Figure 5d shows that the DFS70 KO cells (interphase and
mitosis) present only on the novel substrate do not react
with DFS70 autoantibodies (Fig. 5d). Therefore, when the
substrate is reacted with mono-specific DFS70 sera, a
typical pattern with 10% brightly labelled nuclei (derived
from conventional HEp-2) and 90% negatively stained
nuclei (derived from DFS70 KO cells) is observed. This
substrate eliminates the need for evaluation of mitotic
pattern to distinguish DFS70 from classic patterns (ho-
mogeneous/speckled). Typical reactions obtained using a
DFS70 mono-specific sample on conventional HEp-2 IIF
substrate (Fig. 5e) and novel HEp-2 ELITE/DFS70 KO
substrate (Fig. 5f) emphasize the differences and ease of
interpretation. Fine speckled and homogeneous patterns are
most frequent in ANA positive cases and are associated
with AARD/SARD. These patterns can be distinguished by
granular vs. smooth staining of interphase nuclei and
negative vs. smooth positive staining of mitotic chromatin.
Cases where both speckled and homogeneous patterns co-
occur are challenging to distinguish from the DFS70 pat-
tern. HEp-2 ELITE/DFS70 KO substrate is able to present
all classic ANA patterns (AC-01 to AC-28 with exception
of AC-02) similar to conventional substrates. Representa-
tive results from internal studies using HEp-2 ELITE/
DFS70 KO substrate produced identical classic ANA pat-
terns when reacted with control sera for respective patterns
(Fig. 6). Differential staining was observed only for mono-
specific DFS70 (AC-02) pattern and mixed reactions. In
case of DFS70 mono-specific reaction, the engineered cells
are negative for DFS70 compared to natural HEp-2 cells
which show a strong reaction (Fig. 6). In a few cases, the
novel substrate revealed classic ANAs that were concealed
HEp-2 cell in 
interphase
HEp-2 cell in 
mitosis
Positive homogeneous signal
Positive speckled/fine speckled signal
Negative fluorescence signal
DFS70 positive reaction on 
conventional HEp-2 IIF substrate
Interpretation of DFS70 pattern using conventional vs. engineered HEp-2 substrate
DFS70 positive reaction on HEp-2 

























































































































Fig. 5 A schematic represents the design of the novel HEp-2 ELITE/
DFS70 KO substrate. a–d Schematics for common patterns (DFS70,
homogeneous and speckled) on both interphase and mitotic HEp-2
nuclei in conventional and DFS70 KO cells is described. e Example
of a DFS70 mono-specific reaction on conventional HEp-2 substrate.
f Example of a DFS70 mono-specific reaction on HEp-2 ELITE/
DFS70 KO substrate is shown. Arrows indicate conventional HEp-2
cell nuclei. Negatively stained nuclei are derived from the engineered
DFS70 KO cells that do not express LEDGF/psip1/p75 antigen
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under the intense DFS70 pattern (Fig. 6: examples of fine
speckled, nucleolar and nuclear envelope/homogeneous
reactions co-occurring with DFS70 reaction). The new
method simplifies the interpretation of DFS70 pattern even
in challenging cases presenting low titers of antibodies and
mixed patterns.
The preliminary evaluation of HEp-2 ELITE/DFS70 KO
substrate was performed by the Laboratory of Clinical
Pathology at the San Antonio Hospital located in Tol-
mezzo, Italy, using a total of 746 cases across five different
cohorts. The study included 148 cases suspected of having
DFS70 autoantibodies, which were initially identified by
conventional HEp-2 IIF (Inova Diagnostics, USA). The
other cases evaluated include healthy donors (100), infec-
tious disease positive patients (118), patients diagnosed
with an autoimmune disease (138 total; 108 ANA positive
and 30 ANA negative), and a routine ANA screening
population (242) (unpublished results). The 148 cases
suspected of DFS70 pattern by conventional HEp-2 IIF
were analyzed using a CLIA assay (QUANTA Flash
DFS70, Inova Diagnostics) and IIF using HEp-2 ELITE/
DFS70 KO substrate. The CLIA assay determined 61%
(90) of the 148 cases to be positive and 39% (58) as neg-
ative. The HEp-2 ELITE/DFS70 KO analysis confirmed
65% (96) of the 148 cases to be positive. New IIF substrate
produced a 94% (85) positive agreement with the 90 CLIA
positive cases. In addition, the new substrate confirmed
approximately a fifth (19%) of the 58 CLIA negative cases
to be positive for DFS70 autoantibodies. The new HEp-2
ELITE/DFS KO substrate produced an improved overall
sensitivity of 65% compared to 61% obtained with CLIA.
The other study cohorts were also tested for DFS70 pres-
ence using the HEp-2 ELITE/DFS70 KO substrate. The
routine ANA screening population had five cases (2%)
Fig. 6 Shows examples of homogeneous, mitochondrial, centromere,
speckled, nucleolar and DFS70 (mono-specific) reactions on the new
HEp-2 ELITE/DFS70 KO substrates. Arrows represent conventional
HEp-2 cell nuclei intensely stained with DFS70 reactive serum. For
classic ANA patterns both conventional and engineered HEp-2 cells
show identical reactions. Bottom panel shows examples of mixed
patterns revealed on the HEp-2 ELITE DFS70 KO substrates when
DFS70 pattern co-exist with another classic ANA pattern. Arrows
indicate conventional HEp-2 with strong DFS70 pattern. Less
intensely labeled DFS70 KO cells are able to reveal fine speckled,
nucleolar and nuclear envelope/homogeneous reactions
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identified to be DFS70 positive and the healthy donor
population had two cases (2%) as positive. Infectious dis-
ease (118) and autoimmune cases (both ANA positive and
negative) did not identify any DFS70 positive cases using
this improved IIF substrate.
Conclusion
DFS70 autoantibodies have been reported by numerous
groups not only in various autoimmune and non-autoim-
mune disease states but also in healthy population. DFS70
autoantibodies present a unique interpretation challenge for
clinical labs that use the recommended HEp-2 IIF for
screening of ANAs. Currently available commercial assays
for the confirmation of DFS70 autoantibodies do not
always agree with DFS70 suspicion by IIF. Over and under
estimation of DFS70 pattern using conventional IIF com-
plicates the ANA screening work flow by increasing the
number of reflex tests which further increases the cost of
implementing the diagnostic algorithm (Fig. 3). The novel
HEp-2 ELITE/DFS70 KO substrate presented here sim-
plifies the interpretation of DFS70 pattern (Fig. 5) and
improves the overall accuracy of the ANA screening
algorithm by revealing classic ANA reactions masked by
DFS70. This new substrate can screen and confirm mono-
specific or isolated DFS70 positive cases in one step while
adhering to the standard IIF methodology and not com-
promising on the abilities of a conventional HEp-2 IIF
method (Fig. 6). A major subset of the routine ANA
screening population consists of ANA negative and DFS70
positive cases which if confirmed with confidence do not
need a clinical follow-up (Fig. 7). The current generation
of DFS70 specific confirmatory assays neither provide high
levels of agreement with IIF results nor are able to confirm
the mono-specific/isolated DFS70 positivity, thereby
complicating the ANA screening and confirmation algo-
rithm (Fig. 3). Therefore, to eliminate suspicion of SARD/
AARD, clinical labs rely on a large panel of ANA specific
assays even in cases of DFS70 suspicion (Fig. 3). Imple-
mentation of the newly described HEp-2 ELITE/DFS70
KO substrate as the first step IIF, significantly improves
and simplifies the ANA screening and confirmation algo-
rithm (Fig. 6). The new HEp-2 ELITE/DFS70 KO sub-
strate overcomes the limitations associated with accurate
interpretation of DFS70 pattern and increases the overall
accuracy of the HEp-2 IIF method for screening of ANAs.
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